White label – Pompe disease - ClinicalTrials.eu

Study of efgartigimod given by IV infusion in adolescents aged 12-17 years with chronic immune thrombocytopenia

Recruiting

4 1
Investigated Drugs:
- Efgartigimod Alfa
+2
Study of inhaled aprotinin for treatment of moderate to severe acute respiratory distress syndrome

Recruiting

3 1
Investigated Drugs:
- APROTININ
Study of bone marrow mesenchymal cells with biomaterial to treat delayed or non-healing long bone fractures using ORTHOALLO-BM-MSC and MBCP+ in adult patients

Recruiting

3 1 1
Investigated Drugs:
- ALLOGENEIC BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS, FROM SELECTED DONORS
Effect of atomoxetine on learning dynamics in healthy adults: a study comparing single dose atomoxetine 40 mg with placebo

Recruiting

2 1 1
Investigated Drugs:
- Gelatin
- Atomoxetine
Study of ALKS 2680 to treat excessive daytime sleepiness in people with idiopathic hypersomnia

Recruiting

2 1
Investigated Diseases:
- Hypersomnia
Investigated Drugs:
- Alks 2680
Study of Dapagliflozin for Reducing Cardiovascular Events in Adults with High Blood Pressure

Recruiting

3 1 1
Investigated Drugs:
- Dapagliflozin
Study of ranolazine in patients with ST-elevation heart attack and multiple blocked coronary arteries to improve small blood vessel function

Recruiting

2 1 1 1
Investigated Diseases:
- Acute myocardial infarction
Investigated Drugs:
- Ranolazine
Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger’s Disease) to Reduce Protein in Urine

Recruiting

3 1

+6
Study of inhaled LTI-03 for safety and effectiveness in patients with Idiopathic Pulmonary Fibrosis who may be receiving standard antifibrotic therapy

Recruiting

2 1
Investigated Drugs:
- LTI-03
Study of Janus kinase inhibitor dose reduction in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis who have achieved low disease activity

Recruiting

3 1 1 1
Investigated Diseases:
Investigated Drugs:

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies